Concepedia

Johannes Beeslaar

JB

Statistics

Publications

12

Citations

469

H-Index

10

Active since

2012

Affiliations

Pfizer (United Kingdom)(Current)

Pfizer (United States)

Aarhus University Hospital

Poznan University of Medical Sciences

Tampere University

Johannes Beeslaar is an author at Pfizer (United Kingdom) specializing in infectious diseases, vaccination, and veterinary medicine.

ORCID

Publications per year

2012–2025

12

Publications

12

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

Peter Richmond, Helen Marshall, Michael D. Nissen et al. · The Lancet Infectious Diseases · 2012 · 131 citations · Full text

, , +12

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

Lars Østergaard, Timo Vesikari, Judith Absalon et al. · New England Journal of Medicine · 2017 · 72 citations · Full text

, , +17

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

Timo Vesikari, Lars Østergaard, Javier Díez‐Domingo et al. · Journal of the Pediatric Infectious Diseases Society · 2015 · 59 citations · Full text

, , +17

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

Timo Vesikari, Jacek Wysocki, Johannes Beeslaar et al. · Journal of the Pediatric Infectious Diseases Society · 2016 · 42 citations · Full text

, , +17

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial

Helen Marshall, Peter Richmond, Johannes Beeslaar et al. · The Lancet Infectious Diseases · 2016 · 39 citations · Full text

, , +14

1–5 of 12